These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33235031)

  • 41. Renal Denervation in the Management of Hypertension: A Meta-Analysis of Sham-Controlled Trials.
    Dahal K; Khan M; Siddiqui N; Mina G; Katikaneni P; Modi K; Azrin M; Lee J
    Cardiovasc Revasc Med; 2020 Apr; 21(4):532-537. PubMed ID: 31420197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pulse Wave Velocity Predicts Response to Renal Denervation in Isolated Systolic Hypertension.
    Fengler K; Rommel KP; Hoellriegel R; Blazek S; Besler C; Desch S; Schuler G; Linke A; Lurz P
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28515119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal denervation for resistant hypertension and beyond.
    Laffin LJ; Bakris GL
    Adv Chronic Kidney Dis; 2015 Mar; 22(2):133-9. PubMed ID: 25704350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of renal denervation in elderly patients with resistant hypertension.
    Ziegler AK; Bertog S; Kaltenbach B; Id D; Franke J; Hofmann I; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2015 Aug; 86(2):299-303. PubMed ID: 23983010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current technologies: an introduction.
    Daemen J
    EuroIntervention; 2013 May; 9 Suppl R():R75-82. PubMed ID: 23732160
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials.
    Stavropoulos K; Patoulias D; Imprialos K; Doumas M; Katsimardou A; Dimitriadis K; Tsioufis C; Papademetriou V
    J Clin Hypertens (Greenwich); 2020 Apr; 22(4):572-584. PubMed ID: 32049436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Now That Renal Denervation Works, How Do We Proceed?
    Papademetriou V; Stavropoulos K; Doumas M; Tsioufis K
    Circ Res; 2019 Mar; 124(5):693-695. PubMed ID: 30817252
    [No Abstract]   [Full Text] [Related]  

  • 48. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.
    Böhm M; Mahfoud F; Townsend RR; Kandzari DE; Pocock S; Ukena C; Weber MA; Hoshide S; Patel M; Tyson CC; Weil J; Agdirlioglu T; Fahy M; Kario K
    Eur Heart J; 2019 Mar; 40(9):743-751. PubMed ID: 30608521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry.
    Vogel B; Kirchberger M; Zeier M; Stoll F; Meder B; Saure D; Andrassy M; Mueller OJ; Hardt S; Schwenger V; Strothmeyer A; Katus HA; Blessing E
    Clin Res Cardiol; 2014 Feb; 103(2):117-24. PubMed ID: 24126436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.
    Yerasi C; Baker NC; Jonnalagadda AK; Torguson R; Singh S; Vies J; Waksman R
    J Am Soc Hypertens; 2015 Dec; 9(12):959-65. PubMed ID: 26687550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term verification of functional and structural renal damage after renal sympathetic denervation.
    Dörr O; Liebetrau C; Möllmann H; Gaede L; Troidl C; Wiebe J; Renker M; Bauer T; Hamm C; Nef H
    Catheter Cardiovasc Interv; 2016 Jun; 87(7):1298-303. PubMed ID: 26699846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go?
    Briasoulis A; Bakris G
    Can J Cardiol; 2015 May; 31(5):642-8. PubMed ID: 25828371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.
    Esler MD; Böhm M; Sievert H; Rump CL; Schmieder RE; Krum H; Mahfoud F; Schlaich MP
    Eur Heart J; 2014 Jul; 35(26):1752-9. PubMed ID: 24898552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease.
    Prejbisz A; Kądziela J; Lewandowski J; Florczak E; Zylińska E; Kłopotowski M; Witkowski A; Januszewicz A
    Clin Res Cardiol; 2014 Mar; 103(3):251-3. PubMed ID: 24322784
    [No Abstract]   [Full Text] [Related]  

  • 55. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.
    Flack JM; Bhatt DL; Kandzari DE; Brown D; Brar S; Choi JW; D'Agostino R; East C; Katzen BT; Lee L; Leon MB; Mauri L; O'Neill WW; Oparil S; Rocha-Singh K; Townsend RR; Bakris G;
    J Am Soc Hypertens; 2015 Oct; 9(10):769-779. PubMed ID: 26362830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergy of pulmonary vein isolation and catheter renal denervation in atrial fibrillation complicated with uncontrolled hypertension: Mapping the renal sympathetic nerve and pulmonary vein (the pulmonary vein isolation plus renal denervation strategy)?
    Chen S; Kiuchi MG; Yin Y; Liu S; Schratter A; Acou WJ; Meyer C; Pürerfellner H; Chun KRJ; Schmidt B
    J Cardiovasc Electrophysiol; 2019 May; 30(5):658-667. PubMed ID: 30680830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.
    Böhm M; Mahfoud F; Ukena C; Hoppe UC; Narkiewicz K; Negoita M; Ruilope L; Schlaich MP; Schmieder RE; Whitbourn R; Williams B; Zeymer U; Zirlik A; Mancia G;
    Hypertension; 2015 Apr; 65(4):766-74. PubMed ID: 25691618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal artery sympathetic denervation: observations from the UK experience.
    Sharp AS; Davies JE; Lobo MD; Bent CL; Mark PB; Burchell AE; Thackray SD; Martin U; McKane WS; Gerber RT; Wilkinson JR; Antonios TF; Doulton TW; Patterson T; Clifford PC; Lindsay A; Houston GJ; Freedman J; Das N; Belli AM; Faris M; Cleveland TJ; Nightingale AK; Hameed A; Mahadevan K; Finegold JA; Mather AN; Levy T; D'Souza R; Riley P; Moss JG; Di Mario C; Redwood SR; Baumbach A; Caulfield MJ; Dasgupta I
    Clin Res Cardiol; 2016 Jun; 105(6):544-52. PubMed ID: 26802018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insights on safety and efficacy of renal artery denervation for uncontrolled-resistant hypertension in a high risk population with chronic kidney disease: first Italian real-world experience.
    Marin F; Fezzi S; Gambaro A; Ederle F; Castaldi G; Widmann M; Gangemi C; Ferrero V; Pesarini G; Pighi M; Ribichini FL
    J Nephrol; 2021 Oct; 34(5):1445-1455. PubMed ID: 33481223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension.
    Mahfoud F; Renkin J; Sievert H; Bertog S; Ewen S; Böhm M; Lengelé JP; Wojakowski W; Schmieder R; van der Giet M; Parise H; Haratani N; Pathak A; Persu A
    JACC Cardiovasc Interv; 2020 Feb; 13(4):471-484. PubMed ID: 32081241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.